CLDF Title
Home | Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   OTHER
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information: FDA approves AbbVie's hepatitis C drug

FDA approves AbbVie's hepatitis C drug

Last Updated: 2017-08-03

By Reuters Staff

(Reuters) - The U.S. Food and Drug Administration on Thursday approved AbbVie Inc's drug Mavyret (glecaprevir and pibrentasvir) to treat certain adults with chronic hepatitis C.

Mavyret aims to treat hepatitis C genotypes 1 through 6 in previously untreated adults with or without mild cirrhosis, including patients with moderate to severe kidney disease and those on dialysis.

Mavyret is the only 8-week duration treatment approved for all hepatitis C genotypes, the FDA said. A standard treatment for hepatitis C has a duration of 12-weeks or more. (http://bit.ly/2vxrKo3)

An estimated 2.7 million to 3.9 million people in the United States have chronic hepatitis C infection, according to the Centers for Disease Control and Prevention.

 
 
 
 
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2017 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.